Clinical trials: End of Life Patients
Refractory Metastatic Colorectal Cancer
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer
- Trial name
- NCT02860546
- Testing
- TAS-102, nivolumab
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
Lupus Erythematosus, Systemic, Atrioventricular Block
Systemic Lupus Erythematous and Heart Conduction Disorders
Connective tissue diseases have been related to heart conduction disorders. The anti-Ro/SSA antibodies are thought to have a pathogenic role, and they most prevalent in systemic lupus erythematous (SLE).
- Conditions
- Lupus Erythematosus, Systemic, Atrioventricular Block, Sudden Death
- Trial name
- NCT02162992
- Testing
- No intervention
- Where
- Spain
- Volunteers
- 151 people
- Sponsor
- Germans Trias i Pujol Hospital
Myocardial Infarction, Death, Sudden, Cardiac
Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging
Doctors use magnetic resonance imaging (MRI) to obtain detailed pictures of the inside of the body. This study will evaluate a new MRI technique in people who have recently had a heart attack.
- Trial name
- OmegaREMODEL (NCT00729430)
- Testing
- Omega-3 Fatty Acids (Fish Oil Supplements)
- Where
- United States
- Volunteers
- 358 people
- Sponsor
- Brigham and Women's Hospital
Lung Cancer
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT03322540
- Testing
- Pembrolizumab, Epacadostat
- Where
- 101 sites in United States, Australia and 16 more
- Volunteers
- 154 people
- Sponsor
- Incyte Corporation
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
- Trial name
- DAPA-HF (NCT03036124)
- Testing
- Dapagliflozin
- Where
- 419 sites in United States, Argentina and 18 more
- Volunteers
- 4,744 people
- Sponsor
- AstraZeneca
End of Life, Cancer
Enhancing Community Capacity to Improve Cancer Care Delivery
Undertreated patient symptoms and resulting acute care use require approaches that improve symptom-burden. Previously a a lay health worker (LHW)-led symptom screening intervention was developed for patients with advanced cancer.
- Trial name
- NCT04107116
- Testing
- Program participants, Usual Care
- Where
- United States
- Volunteers
- 832 people
- Sponsor
- Stanford University
Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm
Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer
This clinical trial examines a web-based tool, in partnership with Peacefully, Inc, designed to improve end-of-life planning among patients with advanced cancers.
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT05564468
- Testing
- Best Practice, Internet-Based Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fred Hutchinson Cancer Center
Urothelial Cancer
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic…
- Trial name
- NCT02603432
- Testing
- Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
- Where
- 382 sites in United States, Argentina and 27 more
- Volunteers
- 700 people
- Sponsor
- Pfizer
Rare Diseases
FACE for Children With Rare Diseases
Children with ultra-rare or complex rare diseases are routinely excluded from research studies because of their conditions, creating a health disparity.
- Trial name
- FACE-Rare (NCT04855734)
- Testing
- FAmily CEntered (FACE) pACP Intervention
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Children's National Research Institute
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Pulmonary Disease, COPD
Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate a multifaceted intervention to improve the quality of end-of-life communication between patients with COPD and their primary care providers using information about patients preferences for…
- Conditions
- Pulmonary Disease, COPD, Chronic Bronchitis, Emphysema
- Trial name
- NCT00106080
- Testing
- Audit and Feedback
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- VA Office of Research and Development
Sudden Cardiac Death, Sudden Cardiac Arrest
Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study
A multi-center, prospective, randomized controlled clinical trial with 1:1 assignment of treatment and control. This study will evaluate the impact of wearable cardioverter defibrillator use on sudden cardiac death in incident…
- Trial name
- WED-HED (NCT02481206)
- Testing
- Wearable Cardioverter Defibrillator
- Where
- 31 sites in United States
- Volunteers
- 66 people
- Sponsor
- Zoll Medical Corporation
Melanoma
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
The purpose of this study is to assess the safety and tolerability of treatment with Nivolumab in combination with Ipilimumab in subjects with resected Stages IIIB/IIIC/ IV melanoma.
- Trial name
- NCT02970981
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- NYU Langone Health
Health Education, Sudden Infant Death
Study of the Impact of Parental Note Taking on the Effectiveness of Anticipatory Guidance
The delivery of anticipatory guidance is an essential component of pediatric practice. Given the large amount of information to be shared during each encounter and the limited time available, there is a need for an effective and…
- Trial name
- NCT01014169
- Testing
- Note taking
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Carcinoma, Non-Small-Cell Lung
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with boserolimab (MK-5890), MK-4830, MK-0482 in participants with advanced squamous or non-squamous NSCLC that have been…
- Trial name
- NCT04165096
- Testing
- Pembrolizumab, Boserolimab, MK-4830
- Where
- 39 sites in United States, Hungary and 5 more
- Volunteers
- 128 people
- Sponsor
- Merck Sharp & Dohme LLC
Hospice, End of Life
Tandem VR: Synchronized Nature-Based Experiences in Virtual Reality for Hospice Patients and Their Caregivers
Background: Nature-based virtual reality (VR) and other outdoor experiences in head-mounted displays (HMDs) offer powerful, non-pharmacological tools for hospice teams to help patients undergoing end-of-life (EOL) transitions.
- Conditions
- Hospice, End of Life, Palliative Care, Pain
- Trial name
- NCT06186960
- Testing
- Tandem Virtual Reality
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Prisma Health-Upstate
Primary Stage IV Hepatobiliary, Esophageal
Improving Goals of Care Discussion in Advanced Cancer Patients
The goal of this study is to increase and improve Goals of Care discussions for advanced cancer patients by training medical oncologists to conduct these discussions.
- Conditions
- Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma
- Trial name
- NCT02374255
- Testing
- GoC intervention
- Where
- 4 sites in United States
- Volunteers
- 265 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cardiovascular Disease
Cardiovascular Inflammation Reduction Trial
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic…
- Trial name
- CIRT (NCT01594333)
- Testing
- Methotrexate
- Where
- 470 sites in United States, Canada and 1 more
- Volunteers
- 4,786 people
- Sponsor
- Brigham and Women's Hospital
Hunter Syndrome, Mucopolysaccharidosis II (MPS II)
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
Study TKT024EXT was a long-term, single-arm, open-label extension of Study TKT024, a one year Phase 2/Phase 3 registration study.
- Trial name
- NCT00630747
- Testing
- Idursulfase
- Where
- 52 sites in United States, Brazil and 8 more
- Volunteers
- 94 people
- Sponsor
- Shire
Sudden Cardiac Death, Heart Failure
Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study
This study has 2 purposes: The first purpose of the study is to test a new family of Boston Scientific Implantable Cardioverter Defibrillators ("ICDs") and cardiac resynchronization therapy ICDs ("CRT-Ds") and show how well these…
- Trial name
- NOTICE-HF (NCT01227785)
- Testing
- INCEPTA ICD or CRT-D
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Guidant Corporation